Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03855787
Other study ID # URSSTONE
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date November 11, 2019
Est. completion date November 11, 2025

Study information

Verified date July 2023
Source Vanderbilt University Medical Center
Contact Ryan Hsi, MD
Phone 615-343-2036
Email ryan.hsi@vumc.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The rationale for this study is to determine if there is a difference in complications among patients undergoing ureteroscopy for renal stones who receive a stent compared to not receiving a stent postoperatively.


Description:

Kidney stones affect 9% individuals within the United States, and the prevalence is increasing. Over the last few decades, ureteroscopy has become the most commonly performed stone procedure. However the complication rate after ureteroscopy is not insignificant. Reducing morbidity after ureteroscopy would improve patient outcomes and reduce health care utilization. A major contributor to patient morbidity after ureteroscopy is the ureteral stent, which is placed at the time of surgery and left in place 1-2 weeks after surgery. The rationale for utilizing stents is to prevent urinary obstruction from edema or stone fragments. On the other hand, stents cause hematuria, pain, and lower urinary tract symptoms. Additionally, stent-related symptoms are often misdiagnosed as urinary tract infections leading to unnecessary antibiotic use. The clinical utility of ureteral stents after ureteroscopy has not been well studied, specifically a stone located in the kidney. Prior studies on stent-less ureteroscopic procedures have focused on treatment of ureteral stones and not stones located in the kidney, have had restrictive inclusion and exclusion criteria, are primarily from single center institutions, and most being performed ~15 years ago. Surgical techniques and device innovations have changed the procedure since that time. To date, there have been only 2 studies that included stone located in the kidney showing no difference in unplanned hospital revisits, however both combined analyses with ureteral stones and selection bias was an issue for both studies. In addition, there is a lack of studies assessing opiate use, impact of quality of life with stent placement, and loss of work related to stent placement


Recruitment information / eligibility

Status Recruiting
Enrollment 200
Est. completion date November 11, 2025
Est. primary completion date March 11, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - nonobstructing renal stone 1.5cm total stone diameter (if multiple stones, then sum of maximum diameters) or less undergoing ureteroscopy Exclusion Criteria: - age < 18 years - pregnancy status - ureteral stone - preoperative hydronephrosis - indwelling nephrostomy tube - planning bilateral ureteroscopy or subsequent staged ureteroscopy - solitary kidney or eGFR <60 mL/min (CKD stage 3 or greater) - variant anatomy including horseshoe kidney, pelvic kidney, prior urinary tract reconstruction

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Ureteroscopy
Ureteroscopy for 1.5cm or less renal stones.

Locations

Country Name City State
Canada University of Montreal Montréal
United States Brigham and Women's Hospital Boston Massachusetts
United States Penn State Health Hershey Pennsylvania
United States Indiana University Health Physicians Urology Indianapolis Indiana
United States University of California Los Angeles Los Angeles California
United States Vanderbilt University Medical Center Nashville Tennessee
United States University of California Davis Sacramento California
United States University of California San Diego San Diego California

Sponsors (8)

Lead Sponsor Collaborator
Vanderbilt University Medical Center Brigham and Women's Hospital, Indiana University, Penn State Health, Université de Montréal, University of California, Davis, University of California, Los Angeles, University of California, San Diego

Countries where clinical trial is conducted

United States,  Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Total number of complications Total number of complications - Defined as ER visits related to procedure, unanticipated provider visit, and hospitalization 30 days after ureteroscopy
Secondary PROMIS (Patient-Reported Outcomes Measurement Information System) form 6a This survey assesses self-reported consequences of pain on relevant aspects of one's life, including engagement with social, cognitive, emotional, physical, and recreational activities. There are 6 questions on the survey. The survey score uses at T-score metric with a mean of 50 and a standard deviation of 10 in a referent population. A higher score denotes greater pain interference in one's life. baseline to 5-10 days after ureteroscopy
Secondary WISQOL (Wisconsin Stone Quality of Life Questionnaire) This is a disease specific quality-of-life instrument designed to assess the impact on patients of stones in the urinary tract. The survey is a 28-item instrument with a 5-point LIkert scale for each item. There are a total of 140 points total, and a difference of 10 points can be considered clinically significant. baseline to 5-10 days after ureteroscopy
Secondary Cumulative opiate morphine equivalent dosing (MED) This will be the calculated morphine equivalent dosage of all opiate medications that are prescribed after surgery to follow-up at 5-10 days. baseline to 5-10 days after ureteroscopy
Secondary % return to work This is the number of participants that have returned to work at the time of follow-up at 5-10 days divided by the total participants in the group. 5-10 days after ureteroscopy
Secondary Number of participants with symptomatic urinary tract infection (UTI) This will be defined as a urine culture positivity (50,000 cfu/mL or more) with urinary symptoms. Baseline 5-10 days after ureteroscopy
Secondary Number of participants with abnormal imaging findings Hydronephrosis, hematoma, urinoma on routine postop imaging 4-8 weeks after ureteroscopy
See also
  Status Clinical Trial Phase
Recruiting NCT05100017 - Methocarbamol vs Oxybutynin for Management of Pain and Discomfort S/P Ureteroscopy Procedure N/A
Recruiting NCT04559321 - Holmium Vs Trilogy Kidney Stones GUY's 1-2 Phase 3
Completed NCT04332861 - Evaluation of Infection in Obstructing Urolithiasis
Recruiting NCT05578807 - Total Tubeless Percutaneous Nephrolithotomy Without a Ureteral Catheter N/A
Completed NCT03018899 - Paravertebral Block Versus Epidural Anesthesia for Percutaneous Nephrolithotomy N/A
Recruiting NCT02489656 - Quality of Life in Patients With Double Loop Ureteral Stent (JJ Silicone Hydrogel Study) Phase 4
Completed NCT00177086 - Alfuzosin Hydrochloride to Promote Passage of Distal Ureteral Calculi Phase 3
Completed NCT03957109 - Influence of Anesthesia Methods on Surgical Outcomes and Renal Function N/A
Completed NCT05082142 - Tranexamic Acid to Improve Same-day Discharge Rates After Holmium Laser Enucleation of the Prostate (HoLEP) Phase 4
Completed NCT05911945 - Failed Insertion of Ureteral Access Sheath During Flexible Ureterorenoscopy N/A
Recruiting NCT03599297 - Bilateral Synchronous Simultaneous Stone Surgery N/A
Recruiting NCT05701098 - SOUND Pivotal Trial - (Sonomotion stOne comminUtion resoNance ultrasounD) N/A
Completed NCT03888144 - Study of Ketorolac Versus Opioid for Pain After Endoscopy Phase 4
Withdrawn NCT04545528 - The Impact of Nutritional Service in the Stone Clinic on the Patient Urine Collection Results
Recruiting NCT05598671 - Percutaneous Nephrolithotomy Without a Ureteral Catheter N/A
Completed NCT05511545 - The Effect of Education Given to Patients on Pre- and Post-operative Anxiety and Preparation for Discharge N/A
Not yet recruiting NCT04606758 - Fluoroscopic Guided vs US-guided Percutaneous Nephrolithotripsy for the Treatment of Stone Disease N/A
Completed NCT04069338 - Comparison of Lithotripsy Urolithiasis Machines N/A
Completed NCT01329042 - Efficacy of Potassium Sodium Hydrogen Citrate Therapy on Renal Stone Recurrence and/or Residual Fragments After Shockwave Lithotripsy and Percutaneous Nephrolithotomy in Calcium Oxalate Urolithiasis Phase 4
Recruiting NCT04069013 - Standard vs Mini-PCNL for the Treatment of Stone Disease N/A